## Check for updates

### OPEN ACCESS

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

\*CORRESPONDENCE Shuangqing Li 1259594471@qq.com Hong Fan fanhongfan@qq.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

RECEIVED 22 November 2023 ACCEPTED 06 March 2024 PUBLISHED 14 March 2024

#### CITATION

Zeng Q, Xu J, Mu X, Shi Y, Fan H and Li S (2024) Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. *Front. Endocrinol.* 15:1342543. doi: 10.3389/fendo.2024.1342543

### COPYRIGHT

© 2024 Zeng, Xu, Mu, Shi, Fan and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

Qingyue Zeng<sup>1†</sup>, Jiao Xu<sup>1†</sup>, Xingyu Mu<sup>1†</sup>, Yi Shi<sup>1</sup>, Hong Fan<sup>2\*</sup> and Shuangging Li<sup>1\*</sup>

<sup>1</sup>General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China, <sup>2</sup>Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China

### KEYWORDS

dual agonists, incretin based therapy, tirzepatide, type 2 diabetes, obesity, glucagonlike peptide-1 receptor agonists

# A corrigendum on

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis

by Zeng Q, Xu J, Mu X, Shi Y, Fan H and Li S (2023) Front. Endocrinol. 14:1214334. doi: 10.3389/fendo.2023.1214334

In the published article, there was an error in affiliation 1. Instead of "Department of General Practice Medicine Center, West China Hospital, Sichuan University, Chengdu, China,", it should be "General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China."

In the published article, there was an error in the Funding statement. The statement was originally as follows: "The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (Grant Number Z2021JC005)." The correct Funding statement appears below.

"The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Sichuan Science and Technology Program (No. 2017SZYZF0002 and No. 2021YFH0168)."

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.